29 June 2017
News and Views
Links and Services
A study in June's issue of the Alimentary Pharmacology & Therapeutics examines the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis.
Gut microbiota modifiers may have beneficial effects of non-alcoholic fatty liver disease (NAFLD)
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors